Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Micallef Jacob Vincent	2. Issuer Name and Ticker or Trading Symbol VOLITIONRX LTD [ VNRX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Scientific Officer
(Last) (First) (Middle) 13215 BEE CAVE PARKWAY, SUITE 125 GALLERIA OAKS B	3. Date of Earliest Transaction (MM/DD/YYYY) 7/27/2020
(Street) AUSTIN, TX 78738 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option (Right to Buy)	$2.5	7/27/2020		G ⁽¹⁾	V		65000	2/18/2015	8/18/2020	Common Stock	65000	$0	0	I	Borlaug Limited
Option (Right to Buy)	$3	7/27/2020		G ⁽¹⁾	V		65000	2/18/2016	8/18/2020	Common Stock	65000	$0	0	I	Borlaug Limited
Option (Right to Buy)	$2.5	7/27/2020		G ⁽¹⁾	V	65000		2/18/2015	8/18/2020	Common Stock	65000	$0	65000	D
Option (Right to Buy)	$3	7/27/2020		G ⁽¹⁾	V	65000		2/18/2016	8/18/2020	Common Stock	65000	$0	65000	D
Option (Right to Buy)	$4	7/27/2020		G ⁽²⁾	V		55000	1/23/2016	7/23/2021	Common Stock	55000	$0	0	I	Borlaug Limited
Option (Right to Buy)	$4	7/27/2020		G ⁽²⁾	V	55000		1/23/2016	7/23/2021	Common Stock	55000	$0	55000	D

Explanation of Responses:
(1)	The option to purchase an aggregate of 130,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Borlaug Limited ("Borlaug"), a consulting firm, on August 18, 2014 under the Issuer's 2011 Equity Incentive Plan (the "2011 Plan"). Dr. Micallef is a controlling director of Borlaug and has voting and dispositive control over the Common Stock issuable to Borlaug upon the exercise of the option. The option was then transferred by Borlaug to Dr. Micallef on July 27, 2020.
(2)	The option to purchase 55,000 shares of Common Stock of the Issuer was granted to Borlaug on July 23, 2015 under the Issuer's 2011 Plan. The option was then transferred by Borlaug to Dr. Micallef on July 27, 2020.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Micallef Jacob Vincent 13215 BEE CAVE PARKWAY SUITE 125 GALLERIA OAKS B AUSTIN, TX 78738			Chief Scientific Officer